- Home
- ATAI vs NKTR Comparison
ATAI vs NKTR Comparison
Compare ATAI & NKTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATAI
- NKTR
- Stock Information
- Founded
- ATAI 2018
- NKTR 1990
- Country
- ATAI Germany
- NKTR United States
- Employees
- ATAI N/A
- NKTR N/A
- Industry
- ATAI Biotechnology: Pharmaceutical Preparations
- NKTR Biotechnology: Pharmaceutical Preparations
- Sector
- ATAI Health Care
- NKTR Health Care
- Exchange
- ATAI Nasdaq
- NKTR Nasdaq
- Market Cap
- ATAI 280.2M
- NKTR 247.9M
- IPO Year
- ATAI 2021
- NKTR 1994
- Fundamental
- Price
- ATAI $1.99
- NKTR $0.93
- Analyst Decision
- ATAI Strong Buy
- NKTR Strong Buy
- Analyst Count
- ATAI 4
- NKTR 5
- Target Price
- ATAI $9.00
- NKTR $4.50
- AVG Volume (30 Days)
- ATAI 4.9M
- NKTR 3.0M
- Earning Date
- ATAI 03-27-2025
- NKTR 03-07-2025
- Dividend Yield
- ATAI N/A
- NKTR N/A
- EPS Growth
- ATAI N/A
- NKTR N/A
- EPS
- ATAI N/A
- NKTR N/A
- Revenue
- ATAI $331,000.00
- NKTR $93,137,000.00
- Revenue This Year
- ATAI $80.07
- NKTR $12.15
- Revenue Next Year
- ATAI N/A
- NKTR N/A
- P/E Ratio
- ATAI N/A
- NKTR N/A
- Revenue Growth
- ATAI N/A
- NKTR 5.53
- 52 Week Low
- ATAI $1.03
- NKTR $0.63
- 52 Week High
- ATAI $2.85
- NKTR $1.93
- Technical
- Relative Strength Index (RSI)
- ATAI 51.96
- NKTR 53.83
- Support Level
- ATAI $1.94
- NKTR $0.92
- Resistance Level
- ATAI $2.16
- NKTR $1.08
- Average True Range (ATR)
- ATAI 0.34
- NKTR 0.09
- MACD
- ATAI -0.03
- NKTR 0.03
- Stochastic Oscillator
- ATAI 48.38
- NKTR 65.63
About ATAI ATAI Life Sciences N.V.
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine. The business operates geographically in two regions being the United States and Germany.
About NKTR Nektar Therapeutics
Nektar Therapeutics is a biopharmaceutical company. It has wholly-owned research and development pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. In oncology, The company is focused on activating the immune system natural tumor-fighting mechanisms, and it will be studying several immuno-oncology drug candidates in the clinic for a variety of cancer indications. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In virology, the company believes selective immuno-modulators can be useful in addressing viral infections in people. The group derives revenue from the United States and the Rest of the World.